UMMS Affiliation

Center for Health Policy and Research; Clinical Pharmacy Services; Commonwealth Medicine

Publication Date


Document Type



Health Services Administration | Health Services Research | Pharmacy and Pharmaceutical Sciences | Virus Diseases


An evaluation of the effectiveness of HCV genotype 1 treatment with Harvoni® (ledipasvir/sofosbuvir) as measured by a sustained virological response (SVR) of 12 weeks in the MassHealth fee-for-service and Primary Care Clinician plan population. The analysis concluded that treatment was associated with a a high rate of SVR12, which means that Hepatitis C is not detected in the blood after 12 weeks.


Hepatitis C, Harvoni, ledipasvir, sofosbuvir, HCV genotype 1

Rights and Permissions

© 2017 University of Massachusetts Medical School

Journal/Book/Conference Title

2017 Academy of Managed Care and Specialty Pharmacy Annual Conference


Presented at the Academy of Managed Care and Specialty Pharmacy Annual Conference 2017.



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.